MASP-2 Inhibitor Selective Lectin Pathway Complement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective drugs that specifically inhibit complement activation, particularly in conditions like disseminated intravascular coagulation, where complement activation contributes to tissue injury and inflammation, and existing therapies do not differentiate between various complement pathways, potentially disrupting essential immune functions.
Innovation Solution
Development of a MASP-2 inhibitory agent, such as a MASP-2 antibody or fragment, that selectively inhibits the lectin-dependent complement activation pathway without affecting the classical pathway, thereby targeting MASP-2-dependent complement activation to treat conditions like disseminated intravascular coagulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a complement inhibitory drug is developed to treat disease states, then complement-mediated tissue injury is reduced, but no drugs have been approved for human use that specifically target and inhibit complement activation
Solution Approach 1:
The invention segments the complement system into distinct pathways (classical, lectin, alternative) and develops inhibitors that specifically target individual pathways or components. This segmentation allows for selective inhibition of harmful complement activation while preserving beneficial pathway functions, addressing the lack of approved drugs by providing targeted therapeutic approaches.
Solution Approach 2:
The invention applies local quality by creating inhibitors with specific binding characteristics for particular complement components or pathways. Different inhibitors are designed with different specificities - some target the classical pathway, others the lectin pathway, and others the alternative pathway, allowing tailored treatment based on the specific disease mechanism.
2Object-affected harmful factors
If existing therapies inhibit complement activation, then tissue injury is reduced, but they do not differentiate between various complement pathways, potentially disrupting essential immune functions
Solution Approach 1:
The invention divides complement inhibition into pathway-specific segments, allowing selective targeting of the harmful pathway while preserving beneficial pathways. This segmentation enables therapists to choose which pathway to inhibit based on the specific disease context, maintaining immune versatility.
Solution Approach 2:
Different inhibitors are designed with different local specificities - some inhibit C1q (classical pathway), others inhibit MBL (lectin pathway), and others inhibit factors specific to the alternative pathway. This local quality ensures that only the intended pathway is affected, preserving other immune functions.
3Object-affected harmful factors
If complement activation is inhibited to prevent host cell lysis, then protective inflammatory response is reduced, but the inflammatory response is needed to fight infection
Solution Approach 1:
The invention segments complement inhibition to target only the pathological activation pathways while leaving protective pathways intact. By identifying which pathway is responsible for host cell lysis in a specific disease context and selectively inhibiting only that pathway, the invention preserves infection defense capabilities mediated by other pathways.
Solution Approach 2:
Inhibitors are designed with specific binding properties that allow them to act locally on specific complement components involved in pathological processes. This local action prevents host cell lysis through selective pathway inhibition while maintaining the overall complement system's ability to defend against infection.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.